Table 2.
Follow-up data of rON patients with IVIg treatment
| Patient number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|---|---|---|---|---|---|---|---|---|---|
| Treatment prior to IVIg | AZA CS xsCTX x6 |
AZA IVMP |
PLEX AZA CS |
CTX AZA IVMP |
CTX x 6 PLEX x 2 CS AZA |
AZA CS |
AZA CS PLEX |
AZA CS |
AZA CS |
| Disease duration at IVIg onset (m) | 30 | 47 | 6 | 47 | 40 | 12 | 58 | 15 | 26 |
| Follow up time with IVIg | 36 cyc 31 m |
29 cyc 25 m |
10 cyc 6 m |
24 cyc 20 m |
31 cyc 23 m |
37 cyc 33 m |
40 cyc 36 m |
37 cyc 33 m |
22 cyc 18 m |
| Adverse events | - | - | - | Fever | - | - | - | - | - |
| Attacks the year before IVIg | 1 | 2 | 1 | 3 | 1 | 2 | 1 | 1 | 1 |
| Attacks under IVIg | 1 | - | - | - | 1 | 0 | 0 | 1 | 0 |
| Therapy during IVIg | MM CS | AZA | AZA CS | AZA | MM MTX |
AZA CS |
AZA CS |
AZA CS |
AZA CS |
| EDSS before IVIg | 3.0 | 2.0 | 4.0 | 3.0 | 4.0 | 1.0 | 1.0 | 3.0 | 1.0 |
| EDSS after IVIg | 3.0 | 2.0 | 4.0 | 3.0 | 1.0 | 1.0 | 1.0 | 3.0 | 1.0 |
| VA before IVIg | R-NLP L-0.8 |
R-0.2 L-1.0 |
R-NLP L-1.0 |
R-1.0 L-0.6 |
R-0.1 L-1.0 |
R-0.9 L-0.9 |
R-0.9 L-0.6 |
R-LP L-1.0 |
R-1.0 L-1.0 |
| VA after IVIg | R-NLP L-0.8 |
R-0.2 L-1.0 |
R-NLP L-1.0 |
R-1.0 L-0.6 |
R-0.7 L-1.0 |
R-0.9 L-0.9 |
R-0.9 L-0.6 |
R-LP L-1.0 |
R-1.0 L-1.0 |
IVIg, intravenous immunoglobulin; AZA, azathioprine; CS, oral corticosteroids; CTX, cylclophosphamide; PLEX, plasma exchange; IVMP, intravenous methylprednisolone; MM, mycophenolate mofetil; MTX, methotrexate; Cyc, cycle; m, month; VA, visual acuity; R, right; L, left; NLP, negative light perception; LP, light perception.